Amitiza Dosing
For chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC), use Amitiza (lubiprostone) 24 mcg twice daily; for irritable bowel syndrome with constipation (IBS-C) in women, use 8 mcg twice daily. 1
Standard Dosing by Indication
Chronic Idiopathic Constipation (CIC)
- Dose: 24 mcg twice daily 2, 1
- Approved for both men and women
- Effects typically manifest within 2 days in responders 2
Opioid-Induced Constipation (OIC)
- Dose: 24 mcg twice daily 1
- Approved for adult patients with chronic, non-cancer pain
- Important limitation: Not established for patients taking diphenylheptane opioids (e.g., methadone) 1
- Most effective with phenanthrene opioids (e.g., oxycodone) and phenylpiperidine opioids (e.g., fentanyl) 3
Irritable Bowel Syndrome with Constipation (IBS-C)
- Dose: 8 mcg twice daily 2, 1
- FDA-approved only for women ≥18 years old 1
- Lower dose reduces nausea risk while maintaining efficacy 4
Dose Adjustments
Hepatic Impairment
Reduce dose to 8 mcg twice daily in patients with moderate or severe hepatic insufficiency 2. This is critical because lubiprostone undergoes hepatic metabolism, though systemic absorption is negligible 2.
No Renal Adjustment Required
Lubiprostone does not cause clinically meaningful electrolyte imbalances or affect renal function markers (BUN, creatinine) in short-term or long-term use 5.
Administration Instructions
- Take with food and water to minimize nausea 2, 1
- Swallow capsules whole; do not break apart or chew 1
- The risk of nausea is dose-dependent and significantly reduced when taken with meals 2
Duration of Treatment
- No time limit specified in FDA labeling 1
- Clinical trials evaluated 4 weeks for CIC 2 and 12 weeks for OIC 6
- Long-term safety demonstrated up to 48 weeks 5
- Periodically reassess need for continuous therapy 1
Common Pitfalls and Management
Nausea (Most Common Side Effect)
- Occurs in approximately 29% of CIC patients but only 9% discontinue 2, 1
- Lower in males (8%) and elderly patients (19%) 1
- Mitigate by ensuring administration with food and water 2
- Typically mild to moderate; severe nausea in only 4% 1
Diarrhea
- Occurs in 12% of CIC patients; 2% discontinue 1
- Avoid use in patients with severe diarrhea 1
- Instruct patients to discontinue and contact provider if severe diarrhea develops 1
Dyspnea
- May occur within 30-60 minutes of first dose 1
- Described as chest tightness and difficulty breathing
- Generally resolves within 3 hours but can recur with subsequent doses 1
- More common with 24 mcg dose (3% in CIC) 1
Syncope and Hypotension
- Rare but potentially serious; may require hospitalization 1
- Most cases with 24 mcg dose, often within one hour of first dose 1
- Risk increased with concomitant diarrhea, vomiting, or blood pressure-lowering medications 1
Contraindications
Do not use in patients with known or suspected mechanical gastrointestinal obstruction 1. Evaluate patients with suggestive symptoms before initiating therapy 1.
Clinical Context from Guidelines
The 2023 AGA-ACG guidelines provide a conditional recommendation for lubiprostone in CIC patients who do not respond to over-the-counter agents, based on low certainty evidence 2. The medication can be used as replacement or adjunct to OTC therapies 2. While lubiprostone increases spontaneous bowel movements by 1.98 per week compared to placebo 2, the overall certainty of evidence is considered low due to imprecision in outcomes 2.